Immune dysfunction in bipolar disorder and suicide risk: Is there an association between peripheral corticotropin-releasing hormone and interleukin-1β?

Bipolar Disorders

Volumn 16, Issue 7, 2014, Pages 741-747

  Monfrim, Xênia ^a   Gazal, Marta ^a   De Leon, Pâmela B ^a   Quevedo, Luciana ^a   Souza, Luciano D ^a   Jansen, Karen ^a   Oses, Jean P ^a   Pinheiro, Ricardo T ^a   Silva, Ricardo A ^a   Lara, Diogo R ^b   Ghisleni, Gabriele ^a   Spessato, Barbara ^a   Kaster, Manuella P ^a  

^a CATHOLIC UNIVERSITY OF PELOTAS   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Bipolar disorder; Corticotropin releasing hormone; Interleukin 1 ; Suicide risk

Indexed keywords

ANTIDEPRESSANT AGENT; CORTICOTROPIN RELEASING FACTOR; INTERLEUKIN 1BETA; MOOD STABILIZER; PSYCHEDELIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MOOD; PRIORITY JOURNAL; SUICIDE; YOUNG ADULT; ADOLESCENT; ANALYSIS OF VARIANCE; BLOOD; COMPLICATION; IMMUNE SYSTEM DISEASES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RISK;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BIPOLAR DISORDER; CORTICOTROPIN-RELEASING HORMONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALLUCINOGENS; HUMANS; IMMUNE SYSTEM DISEASES; INTERLEUKIN-1BETA; MALE; PSYCHIATRIC STATUS RATING SCALES; RISK; SUICIDE; YOUNG ADULT;

EID: 84908602245     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12214     Document Type: Article

References (46)

1. Levi F, La Vecchia C, Saraceno B. Global suicide rates. Eur J Public Health 2003; 13: 97-98.
2. Rihmer Z, Akiskal H. Do antidepressants threaten depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 2006; 94: 3-13.
3. Tondo L, Lepri B, Baldessarini RJ. Suicidal risks among 2826 Sardinian major affective disorder patients. Acta Psychiatr Scand 2007; 116: 419-428.
4. Correa H, Campi-Azevedo AC, De Marco L et al. Familial suicide behaviour: association with probands suicide attempt characteristics and 5-HTTLPR polymorphism. Acta Psychiatr Scand 2004; 110: 459-464.
5. Carroll-Ghosh T, Victor BS, Bourgeois JA. Suicide. In: Hales RE, Yudofsky SC eds. Textbook of Clinical Psychiatry. Washington, DC: American Psychiatric Publishing, Inc., 2003: 1457-1483.
6. Manchia M, Hajek T, O'Donovan C et al. Genetic risk of suicidal behavior in bipolar spectrum disorder: analysis of 737 pedigrees. Bipolar Disord 2013; 15: 496-506.
7. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr 2006; 11: 465-471.
8. Pompili M, Gonda X, Serafini G et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord 2013; 15: 457-490.
9. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005; 6: 463-475.
10. Vale W, Spiess J, Rivier C et al. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 1981; 213: 1394-1397.
11. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992; 267: 1244-1252.
12. Valentino RJ, Foote SL, Page ME. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann N Y Acad Sci 1993; 697: 173-188.
13. Stephanou A, Jessop DS, Knight RA et al. Corticotrophin-releasing factor-like immunoreactivity and mRNA in human leukocytes. Brain Behav Immun 1990; 4: 67-73.
14. Ekman R, Servenius B, Castro MG et al. Biosynthesis of corticotropin-releasing hormone in human T-lymphocytes. J Neuroimmunol 1993; 44: 7-13.
15. Karalis K, Sano H, Redwine J et al. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991; 254: 421-423.
16. Marques AH, Cizza G, Sternberg E. Brain-immune interactions and implications in psychiatric disorders. Rev Bras Psiquiatr 2007; 29 (Suppl. 1): S27-S32.
17. Rifflet H, Pol S, Vuillemin E et al. Murderous impulses in two patients with chronic hepatitis C treated with interferon-α. Gastroenterol Clin Biol 1998; 22: 105-106.
18. Nickel T, Sonntag A, Backmund M et al. Depression during therapy with interferon alpha-how long should an antidepressant treatment last? Pharmacopsychiatry 2005; 38: 102-104.
19. Steiner J, Bielau H, Brisch R et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008; 42: 151-157.
20. Tonelli LH, Stiller J, Rujescu D et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand 2008; 117: 198-206.
21. Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev 2011; 22: 189-195.
22. Dermitzaki E, Tsatsanis C, Gravanis A et al. Corticotropin-releasing hormone induces Fas ligand production and apoptosis in PC12 cells via activation of p38 mitogen-activated protein kinase. J Biol Chem 2002; 277: 12280-12287.
23. Park J, Choi HM, Yang HI et al. Increased expression of IL-1 receptors in response to IL-1β may produce more IL-6, IL-8, VEGF, and PGE2 in senescent synovial cells induced in vitro than in presenescent cells. Rheumatol Int 2005; 32: 2005-2010.
24. Oquendo MA, Waternaux C, Brodsky B et al. Suicidal behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters. J Affect Disord 2000; 59: 107-117.
25. Arborelius L, Owens MJ, Plotsky PM et al. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999; 160: 1-12.
26. Mitchell AJ. The role of corticotropin releasing factor in depressive illness: a critical review. Neurosci Biobehav Rev 1998; 22: 635-651.
27. Daban C, Vieta E, Mackin P et al. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005; 28: 469-480.
28. Berrettini WH, Nurnberger JI Jr, Narrow W et al. Cerebrospinal fluid studies of bipolar patients with and without a history of suicide attempts. Ann N Y Acad Sci 1986; 487: 197-201.
29. Banki CM, Bissette G, Arato M et al. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 1987; 144: 873-877.
30. Banki CM, Karmacsi L, Bissette G et al. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 1992; 2: 107-113.
31. Roy A. Hypothalamic-pituitary-adrenal axis function and suicidal behavior indepression. Biol Psychiatry 1992; 32: 812-816.
32. Roy A. Neuropeptides in relation to suicidal behavior in depression. Neuropsychobiology 1993; 28: 184-186.
33. Arato M, Banki CM, Bissette G et al. Elevated CSF CRF in suicide victims. Biol Psychiatry 1989; 25: 355-359.
34. Westrin A, Ekman R, Traskman-Bendz L. Alterations of corticotropin releasing hormone (CRH) and neuropeptide Y (NPY) plasma levels in mood disorder patients with a recent suicide attempt. Eur Neuropsychopharmacol 1999; 9: 205-211.
35. Brunner J, Stalla GK, Stalla J et al. Decreased corticotropin-releasing hormone (CRH) concentrations in the cerebrospinal fluid of eucortisolemic suicide attempters. J Psychiatr Res 2001; 35: 1-9.
36. Geracioti TD Jr, Orth DN, Ekhator NN et al. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans. J Clin Endocrinol Metab 1992; 74: 1325-1330.
37. Geracioti TD Jr, Loosen PT, Orth DN. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry 1997; 42: 165-174.
38. Remlinger-Molenda A, Wojciak P, Michalak M et al. Activity of selected cytokines in bipolar patients during manic and depressive episodes. Psychiatr Pol 2012; 46: 599-611.
39. Soderlund J, Olsson SK, Samuelsson M et al. Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J Psychiatry Neurosci 2011; 36: 114-118.
40. Sáiz PA, García-Portilla P, Paredes B et al. Association study of the interleukin-1 gene complex and tumor necrosis factor alpha gene with suicide attempts. Psychiatr Genet 2008; 18: 147-150.
41. Huang TL, Lee CT. T-helper 1/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression. Psychiatry Clin Neurosci 2007; 61: 415-420.
42. Lindqvist D, Janelidze S, Hagell P et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009; 66: 287-292.
43. Isung J, Mobarrez F, Nordström P et al. Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide. World J Biol Psychiatry 2012; 13: 468-473.
44. Vaughan J, Donaldson C, Bittencourt J et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378: 287-292.
45. Jones SA, Challis JR. Local stimulation of prostaglandin production by corticotropin-releasing hormone in human fetal membranes and placenta. Biochem Biophys Res Commun 1989; 159: 192-199.
46. Paez Pereda M, Sauer J, Perez Castro C et al. Corticotropin-releasing hormone differentially modulates the interleukin-1 system according to the level of monocyte activation by endotoxin. Endocrinology 1995; 136: 5504-5510.